Comparative Pharmacology
Head-to-head clinical analysis: AXIRON versus DEPO TESTOSTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXIRON versus DEPO TESTOSTERONE.
AXIRON vs DEPO-TESTOSTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
One or two pump actuations (30 mg per actuation) applied to the axilla once daily; dose range 30-90 mg daily.
50-400 mg IM every 2-4 weeks
None Documented
None Documented
The terminal elimination half-life of testosterone is approximately 10-100 minutes after intravenous injection, but for Axiron (testosterone topical solution), the apparent half-life is about 1-2 hours due to continued absorption from the skin and distribution/elimination. Clinically, steady state is achieved after about 2 weeks of daily application.
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (about 90%) and about 6% in feces via bile. Approximately 90% of a dose is excreted in urine, with the remainder in feces.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Category C
Category D/X
Androgen
Androgen